España
India
Italia
대한민국
日本
My Account
Benzinga Edge
Benzinga Research
Benzinga Pro
Login
Get Benzinga Pro
Data & APIs
Events
Premarket
Boost
Advertise
Contribute
España
India
Italia
대한민국
日本
Login
Register
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
Earnings
Interviews
Deals
Regulations
Psychedelics
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
Earnings
Interviews
Deals
Regulations
Psychedelics
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Perfect Stock Portfolio
Easy Income Portfolio
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
Comments
Close menu
Loading...
Coya Therapeutics
COYA
NASDAQ
Watchlist
Leave a Comment
Logo brought to you by Benzinga Data
Get Report
Perks
Buy
Compare Brokers
Get Report
Perks
Buy
Compare Brokers
$5.58
At close: Jan 15, 4:00 PM EDT
$6.00
0.42
7.53%
After Hours: 7:58 AM EDT
Get Report
Comment
Coya Therapeutics (COYA) Forecast
News
Earnings
Coya Therapeutics (COYA) Options
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest news for Coya Therapeutics (NASDAQ:COYA) Stock
Coya Therapeutics Stock (NASDAQ: COYA)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Wednesday, December 18, 2024
D. Boral Capital Maintains Buy on Coya Therap...
Benzinga Newsdesk
Coya Therapeutics Provides Enrollment Update ...
Benzinga Newsdesk
Wednesday, December 04, 2024
D. Boral Capital Initiates Coverage On Coya T...
Benzinga Newsdesk
Tuesday, November 19, 2024
Coya Therapeutics Highlights Strategic Vision...
Benzinga Newsdesk
Monday, November 11, 2024
HC Wainwright & Co. Reiterates Buy on Coya Th...
Benzinga Newsdesk
Thursday, November 07, 2024
Chardan Capital Maintains Buy on Coya Therape...
Benzinga Newsdesk
Friday, November 01, 2024
Coya Therapeutics Appoints Arun Swaminathan, ...
Benzinga Newsdesk
Wednesday, October 30, 2024
Chardan Capital Maintains Buy on Coya Therape...
Benzinga Newsdesk
Tuesday, October 29, 2024
Coya Therapeutics' High-Dose Interleukin-2 Misses The Mark In Mid-Stage Alzheimer's Study
Vandana Singh
12 Health Care Stocks Moving In Tuesday's Intraday Session
Benzinga Insights
Coya Therapeutics shares are trading lower. T...
Benzinga Newsdesk
Coya Therapeutics Says Phase 2 Trial Of LD IL...
Benzinga Newsdesk
Monday, October 28, 2024
Coya Therapeutics shares are trading higher a...
Benzinga Newsdesk
Coya Therapeutics Announces Conference Call O...
Benzinga Newsdesk
Tuesday, October 22, 2024
Coya Therapeutics Announces $10M Private Plac...
Benzinga Newsdesk
Monday, September 16, 2024
This Yelp Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Monday
Avi Kapoor
Coya Therapeutics Subcutaneously Administered...
Benzinga Newsdesk
HC Wainwright & Co. Initiates Coverage On Coy...
Benzinga Newsdesk
Monday, August 19, 2024
Coya Therapeutics Promotes Dr. Arun Swaminath...
Benzinga Newsdesk
Monday, August 12, 2024
Coya Therapeutics Q2 EPS $(0.19) Misses $(0.1...
Benzinga Newsdesk
Wednesday, July 31, 2024
Coya Therapeutics Files Intellectual Property...
Benzinga Newsdesk
Thursday, June 20, 2024
Coya Therapeutics Expands Sponsored Research ...
Benzinga Newsdesk
Thursday, June 13, 2024
Rodman & Renshaw Initiates Coverage On Coya T...
Benzinga Newsdesk
Tuesday, June 11, 2024
Coya Therapeutics shares are trading higher a...
Benzinga Newsdesk
Coya Therapeutics Announces Publication Of Ph...
Benzinga Newsdesk
Monday, June 03, 2024
Coya Therapeutics Peer-Reviewed Manuscript Ti...
Benzinga Newsdesk
Tuesday, May 28, 2024
Coya Therapeutics Announces Inclusion In MSCI...
Benzinga Newsdesk
Monday, May 27, 2024
EXCLUSIVE: Coya Therapeutics, Focused On Neurodegenerative Diseases Has Gained 70% Since IPO; CEO Highlights Efforts On Combination Therapy For Rare Diseases
Vandana Singh
Wednesday, May 22, 2024
Coya Therapeutics Completes Controlled Phase ...
Benzinga Newsdesk
Monday, May 20, 2024
Coya Therapeutics Announces The Alzheimer's D...
Benzinga Newsdesk
Thursday, May 09, 2024
Coya Therapeutics Q1 2024 GAAP EPS $(0.35) Mi...
Benzinga Newsdesk
Monday, April 29, 2024
Chardan Capital Maintains Buy on Coya Therape...
Benzinga Newsdesk
Wednesday, March 20, 2024
Chardan Capital Maintains Buy on Coya Therape...
Benzinga Newsdesk
Tuesday, March 19, 2024
Coya Therapeutics FY23 EPS $(0.79) Vs $(4.73)...
Benzinga Newsdesk
Wednesday, March 06, 2024
Coya Therapeutics Presents Biomarker Data On ...
Benzinga Newsdesk
Thursday, February 29, 2024
Coya Therapeutics To Present Data On Immune S...
Benzinga Newsdesk
Thursday, February 22, 2024
Coya Therapeutics To Present Novel Biomarker ...
Benzinga Newsdesk
Wednesday, February 21, 2024
Coya Therapeutics Issues Letter To Stockholde...
Benzinga Newsdesk
Wednesday, February 14, 2024
Greenlight Capital Adds Position In Coya Ther...
Benzinga Newsdesk
Tuesday, February 13, 2024
Coya Therapeutics Licenses IP Rights For Immu...
Benzinga Newsdesk
Monday, February 05, 2024
Coya Therapeutics Secures Key Financing In Its Fight Against Myriad Diseases
Johnny Rice
Tuesday, January 16, 2024
Coya Therapeutics Announces Pipeline Expansio...
Benzinga Newsdesk
Friday, January 05, 2024
Coya Therapeutics Reveals Successful Pre-IND ...
Benzinga Newsdesk
Wednesday, December 13, 2023
Coya Therapeutics' CEO Dr. Howard Berman Issu...
Benzinga Newsdesk
Wednesday, December 06, 2023
Coya Therapeutics Shares Resume Trade
Benzinga Newsdesk
UPDATE: Dr. Reddy's To Pay COYA $4.2M Upon Fi...
Benzinga Newsdesk
Coya Therapeutics Shares To Resume Trade At 7...
Benzinga Newsdesk
Coya Therapeutics Announces $26.5M Private Pl...
Benzinga Newsdesk
Dr. Reddy's To Make $7.5M Upfront Payment To ...
Benzinga Newsdesk
Coya Therapeutics And Dr. Reddy's Laboratorie...
Benzinga Newsdesk
Show More
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch
